company background image
XNCR

Xencor NasdaqGM:XNCR Stock Report

Last Price

US$28.17

Market Cap

US$1.7b

7D

-4.4%

1Y

-21.9%

Updated

28 Nov, 2022

Data

Company Financials +
XNCR fundamental analysis
Snowflake Score
Valuation0/6
Future Growth2/6
Past Performance2/6
Financial Health6/6
Dividends0/6

XNCR Stock Overview

Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases.

Xencor, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Xencor
Historical stock prices
Current Share PriceUS$28.17
52 Week HighUS$42.30
52 Week LowUS$19.36
Beta0.61
1 Month Change-3.89%
3 Month Change4.64%
1 Year Change-21.95%
3 Year Change-26.22%
5 Year Change29.70%
Change since IPO237.77%

Recent News & Updates

Recent updates

Xencor, Inc.'s (NASDAQ:XNCR) Shares May Have Run Too Fast Too Soon

Aug 12
Xencor, Inc.'s (NASDAQ:XNCR) Shares May Have Run Too Fast Too Soon

Xencor, Inc. (NASDAQ:XNCR) Shares Could Be 35% Above Their Intrinsic Value Estimate

Feb 18
Xencor, Inc. (NASDAQ:XNCR) Shares Could Be 35% Above Their Intrinsic Value Estimate

Upgrade: Analysts Just Made A Huge Increase To Their Xencor, Inc. (NASDAQ:XNCR) Forecasts

Aug 06
Upgrade: Analysts Just Made A Huge Increase To Their Xencor, Inc. (NASDAQ:XNCR) Forecasts

It's Unlikely That The CEO Of Xencor, Inc. (NASDAQ:XNCR) Will See A Huge Pay Rise This Year

Jun 20
It's Unlikely That The CEO Of Xencor, Inc. (NASDAQ:XNCR) Will See A Huge Pay Rise This Year

Party Time: Brokers Just Made Major Increases To Their Xencor, Inc. (NASDAQ:XNCR) Earnings Forecasts

Apr 02
Party Time: Brokers Just Made Major Increases To Their Xencor, Inc. (NASDAQ:XNCR) Earnings Forecasts

Don't Ignore The Fact That This Insider Just Sold Some Shares In Xencor, Inc. (NASDAQ:XNCR)

Mar 06
Don't Ignore The Fact That This Insider Just Sold Some Shares In Xencor, Inc. (NASDAQ:XNCR)

Time To Worry? Analysts Are Downgrading Their Xencor, Inc. (NASDAQ:XNCR) Outlook

Mar 02
Time To Worry? Analysts Are Downgrading Their Xencor, Inc. (NASDAQ:XNCR) Outlook

Are Investors Undervaluing Xencor, Inc. (NASDAQ:XNCR) By 39%?

Feb 26
Are Investors Undervaluing Xencor, Inc. (NASDAQ:XNCR) By 39%?

Companies Like Xencor (NASDAQ:XNCR) Can Afford To Invest In Growth

Jan 27
Companies Like Xencor (NASDAQ:XNCR) Can Afford To Invest In Growth

This Insider Has Just Sold Shares In Xencor, Inc. (NASDAQ:XNCR)

Dec 21
This Insider Has Just Sold Shares In Xencor, Inc. (NASDAQ:XNCR)

Shareholders Are Thrilled That The Xencor (NASDAQ:XNCR) Share Price Increased 219%

Dec 15
Shareholders Are Thrilled That The Xencor (NASDAQ:XNCR) Share Price Increased 219%

Shareholder Returns

XNCRUS BiotechsUS Market
7D-4.4%0.2%0.3%
1Y-21.9%-16.1%-20.5%

Return vs Industry: XNCR underperformed the US Biotechs industry which returned -14.4% over the past year.

Return vs Market: XNCR underperformed the US Market which returned -18.5% over the past year.

Price Volatility

Is XNCR's price volatile compared to industry and market?
XNCR volatility
XNCR Average Weekly Movement6.9%
Biotechs Industry Average Movement11.1%
Market Average Movement7.4%
10% most volatile stocks in US Market15.6%
10% least volatile stocks in US Market3.3%

Stable Share Price: XNCR is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 7% a week.

Volatility Over Time: XNCR's weekly volatility (7%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1997254Bassil Dahiyathttps://www.xencor.com

Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It develops Plamotamab, a tumor-targeted antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other solid tumor types; and Tidutamab that is in Phase II clinical trial to treat neuroendocrine tumors.

Xencor, Inc. Fundamentals Summary

How do Xencor's earnings and revenue compare to its market cap?
XNCR fundamental statistics
Market CapUS$1.69b
Earnings (TTM)US$29.92m
Revenue (TTM)US$296.98m

56.4x

P/E Ratio

5.7x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
XNCR income statement (TTM)
RevenueUS$296.98m
Cost of RevenueUS$199.10m
Gross ProfitUS$97.89m
Other ExpensesUS$67.96m
EarningsUS$29.92m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)0.50
Gross Margin32.96%
Net Profit Margin10.08%
Debt/Equity Ratio0%

How did XNCR perform over the long term?

See historical performance and comparison